Currently out of the existing stock ratings of Rachel Vatnsdal, 3 are a SELL (16.67%), 7 are a HOLD (38.89%), 8 are a BUY (44.44%).

Rachel Vatnsdal

Work Performance Price Targets & Ratings Chart

Analyst Rachel Vatnsdal works at JPMORGAN with a stock forecast success ratio of 58.33% fulfilled within 56.57 days on average.

Rachel Vatnsdal’s has documented 43 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RGEN, Repligen at 20-Dec-2023.

Wall Street Analyst Rachel Vatnsdal

Analyst best performing recommendations are on MYGN (MYRIAD GENETICS).
The best stock recommendation documented was for MYGN (MYRIAD GENETICS) at 8/7/2023. The price target of $17 was fulfilled within 2 days with a profit of $0.47 (2.69%) receiving and performance score of 13.45.

Average potential price target upside

AMRS Amyris QDEL Quidel MTD Mettler-Toledo International HSIC Henry Schein DHR Danaher MYGN Myriad Genetics PACB Pacific Biosciences of California PDCO Patterson Companies RGEN Repligen

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

0.65

$0.51 (364.29%)

3.35

11 months ago

2/2 (100%)

$0.06 (10.17%)

10

Buy

1.25

$1.2 (2400.00%)

19

11 months 8 days ago

3/4 (75%)

$2.13 (47.39%)

21

Buy

5

$4.86 (3471.43%)

30

1 years 1 months 2 days ago

7/10 (70%)

$3.68 (278.79%)

819

Hold

2

$1.86 (1328.57%)

2.5

1 years 3 months 15 days ago

1/2 (50%)

$0.55 (37.93%)

2

Hold

1 years 5 months 9 days ago

1/2 (50%)

$7.57 (43.43%)

391

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Rachel Vatnsdal is most bullish on?

Potential upside of $35.95 has been obtained for RGEN (REPLIGEN)

Which stock is Rachel Vatnsdal is most reserved on?

Potential downside of -$6.34 has been obtained for MYGN (MYRIAD GENETICS)

What Year was the first public recommendation made by Rachel Vatnsdal?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?